CeloNova BioSciences, Inc., announced today that it has expanded the areas in which it is commercializing the CATANIA Coronary Stent System with NanoThin Polyzene(R)-F -- a stent system that has not had any stent thrombosis in clinical studies. It is CE Marked and available for purchase throughout Europe and now some Middle Eastern countries with aggressive world-wide expansion ongoing. Concurrently, CeloNova notes that it has received regulatory approval to increase the shelf life for the stent from two years to three years.
The details can be read here.
No comments:
Post a Comment